¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"passive mediated transport"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • passive transport
    ¼öµ¿¿î¹Ý
  • axonal transport
    Ãà»è¿î¹Ý
  • active transport
    ´Éµ¿¿î¹Ý
  • air medical transport
    °øÁßÀÇ·á¼ö¼Û
  • air medical transport system
    Ç×°øÀÇ·á¼ö¼Ûü°è
  • diffusion-limited transport
    È®»êÁ¦ÇÑ¿î¹Ý
  • facilitated transport
    ÃËÁø¿î¹Ý
  • iron transport
    ö¿î¹Ý
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • passive
    ¼öµ¿-, Çǵ¿-
  • passive smoking
    °£Á¢Èí¿¬
  • transport
    ¿î¹Ý
  • axonal transport
    Ãà»è¿î¹Ý
  • membrane transport
    ¸·¿î¹Ý
  • net transport
    ¼ø¿î¹Ý
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý
  • transmembrane transport
    ¸·¿î¹Ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • passive transport
    ¼öµ¿¿î¹Ý
  • active transport
    ´Éµ¿¿î¹Ý
  • axonal transport
    Ãà»è¿î¹Ý
  • catalysed transport
    Ã˸żö¼Û
  • transport component
    ¼ö¼Û¼ººÐ
  • diffusion-limited transport
    È®»êÁ¦ÇÑ¿î¹Ý
  • transport defect
    ¿î¹Ý°áÇÔ
  • facilitated transport
    ÃËÁø¿î¹Ý
  • transport host
    ¿î¹Ý¼÷ÁÖ
  • maximum transport
    ÃÖ´ë¿î¹ÝÄ¡, ÃÖ´ëÀ̵¿Ä¡
  • maximum tubular transport
    ÃÖ°í¿ä¼¼°üÀ̵¿Ä¡
  • membrane transport
    ¸·¿î¹Ý
  • transport medium
    ¿î¹Ý¹èÁö
  • net transport
    ¼ø¿î¹Ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Tm => transport maximum
    ÃÖ´ëÀ̵¿Ä¡
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • gas transport
    °¡½º¿î¹Ý(ê¡Úæ).
  • glucose transport protein unit
    Æ÷µµ´ç ¿î¹Ý ´Ü¹é ´ÜÀ§(GLUT)
  • piece, transport
    ¿î¹Ý¼ººÐ, ¼ö¼Û¼ººÐ
  • agglutination, passive
    ¼öµ¿ÀÀÁý
  • appreciation of passive movement
    ¼öµ¿¿îµ¿°¨°¢.
  • hemagglutination, passive
    ¼öµ¿ Ç÷±¸ÀÀÁý
  • hemagglutination, reversed passive
    ¿ª¼öµ¿ Ç÷±¸ÀÀÁý¹ÝÀÀ
  • immunity, passive
    ¼öµ¿¸é¿ª
  • immunization, passive
    ¼öµ¿¸é¿ª
  • indirect passive agglutination
    °£Á¢¼öµ¿ÀÀÁý(¹ÝÀÀ).
  • personality disorder, passive
    ¼öµ¿¼º(áôÔÑàõ) ÀΰÝÀå¾Ö
  • personality disorder, passive-aggressive
    ¼öµ¿°ø°Ý¼º ÀΰÝÀå¾Ö
  • personality, passive aggresive
    ¼öµ¿°ø°Ý¼º ÀΰÝ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³ À̵¿
  • axonal transport= axoplasmic transport
    Ãà»è ¿î¹Ý(õîÞþê¡Úæ)
  • downhill transport =passive t.
    Çǵ¿¿î¹Ý(ù¬ÔÑê¡Úæ).
  • passive transport
    Çǵ¿Àû ¿î¹Ý(¡­ê¡Úæ).
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³ °ú¹Î¹ÝÀÀ
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
  • carrier mediated diffusion
    ´ãü(¸Å°³) È®»ê.
  • cell mediated hypersensitivity
    ¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
  • cell mediated immunity
    ¼¼Æ÷¼º¸é¿ª.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷(¸Å°³)¸é¿ª°áÇÌÁõÈıº.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷¼º¸é¿ª°áÇÌÁõÈıº.
  • cell mediated lympholysis
    ¼¼Æ÷¸Å°³ ¸²ÇÁ±¸¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷¸Å°³¼º ¹ÝÀÀ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transport host
    ¿î¹Ý¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • passive mediated transport
    ¼öµ¿ ¸Å°³¿î¹Ý(áôÔÑØÚË¿ê¡Úæ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • mediated transport
    ¸Å°³¼ö¼Û(ØÚË¿âÃáê)
  • passive transport
    ¼öµ¿ ¼ö¼Û(áôÔÑâÃáê)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • F-mediated transduction
    F¸Å°³(ØÚË¿) ÇüÁúµµÀÔ(û¡òõÓôìý)
  • intron-mediated recombination
    ÀÎÆ®·ÐÁß°³(ñéË¿) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • prophage-mediated conversion
    ÇÁ·ÎÆäÀÌÁö ¸Å°³ Àüȯ(ØÚË¿ï®üµ)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
  • passive agglutination
    ¼öµ¿ ÀÀÁý(áôÔÑëêó¢)
  • passive anaphylaxis
    ¼öµ¿(áôÔÑ) ¾Æ³ªÇʶô½Ã½º
  • passive diffusion
    ¼öµ¿ È®»ê(áôÔÑüªß¤)
  • passive hemagglutination
    ¼öµ¿ Ç÷¾×ÀÀÁý(áôÔÑúìäûëêó¢)
  • passive hemolysis
    ¼öµ¿¿ëÇ÷(áôÔÑéÁúì)
  • passive immunity
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transport
    ¼ö¼Û, ¿î¹Ý
  • passive
    Çǵ¿ÀÇ, ¼öµ¿ÀÇ, ¼Ò±ØÀûÀÎ
  • passive movement
    ¼öµ¿¿îµ¿, Çǵ¿¿îµ¿
  • passive shimming
    ¼öµ¿º¸Á¤
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
TM technology management; tectorial membrane; temperature by mouth; temporalis muscle; temporomandibula...
PCA   1) Passive Cutaneous Araphylaxis
  2) Posterior Cerebral Artery
CPC central posterior curve; cerebellar Purkinje cell; cerebral palsy clinic; cerebral performance categ...
CPM central pontine myelinosis; chlorpheniramine maleate; continuous passive motion; critical path metho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CTE Constitutive Transport Element
ETC Electron transport chain
FATP Fatty acid transport protein
HAChT High affinity choline transport
IFT Intraflagellar transport
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carrier mediated transport
    ¿î¹Ýü ¸Å°³ À̵¿
  • passive transport
    Çǵ¿Àû ¿î¹Ý, Çǵ¿Àû À̵¿, ¼öµ¿Àû À̵¿
  • active transport
    ´Éµ¿ À̵¿
    È®»ê¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó ¿î¹Ýü¿¡ ÀÇÇØ ¿¡³ÊÁö¸¦ ¼ÒºñÇØ °¡¸ç ³óµµ¿¡ ¿ªÇàÇØ¼­ ¹°ÁúÀÌ À̵¿µÇ´Â Çö»ó.
  • axonal transport
    Ãà»è ¿î¹Ý
  • carbon dioxide transport
    ÀÌ»êȭź¼Ò ¿î¹Ý
  • co-transport
    °øµ¿ ¿î¹Ý, °øµ¿ À̵¿, °øµ¿ ¼ö¼Û)
  • downhill transport
    Çǵ¿ ¿î¹Ý
  • oxygen transport mechanism
    »ê¼Ò ¿î¹Ý ±âÀü
  • sodium transport system
    ³ªÆ®·ý ¿î¹Ý°è
  • transport
    ¼ö¼Û, ¿î¼Û
    »ý¹°°è¿¡ ÀÖ´Â ¹°ÁúÀÇ À̵¿À¸·Î¼­, ƯÈ÷ ¼¼Æ÷ÀÇ ³»¿Ü³ª »óÇÇÃþÀ» ÅëÇØ¼­ À̵¿ÇÏ´Â °Í.
  • transport oxygen
    »ê¼Ò ¿î¹Ý
  • virus transport medium
    ¹ÙÀÌ·¯½º ¿î¼Û ¹èÁö
  • aldosterone-mediated sodium
    ¾Ëµµ½ºÅ×·Ð Áß°³µÈ ³ªÆ®·ý
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
passive transport <biochemistry, physiology> The movement of a substance, usually across a plasma membrane, by a mechanism that does not require metabolic energy.
See: active transport, transport protein, facilitated diffusion, ion channels.
(18 Nov 1997)
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
cell-mediated reaction Immunological reaction of the delayed type, involving chiefly T lymphocytes, important in host defense against infection, in autoimmune diseases, and in transplant rejection.
See: skin test.
(05 Mar 2000)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
passive Neither spontaneous nor active, not produced by active efforts.
Origin: L. Passivus
(18 Nov 1997)
passive agglutination Agglutination of particles that have been coated with soluble antigen, by antiserum specific for the adsorbed antigen.
Synonym: indirect agglutination.
(05 Mar 2000)
passive-aggressive behaviour Apparently compliant behaviour, with intrinsic obstructive or stubborn qualities, to cover deeply felt aggressive feelings that cannot be more directly expressed.
(05 Mar 2000)
passive-aggressive personality A personality disorder in which aggressive feelings are manifested in passive ways, especially through mild obstructionism and stubbornness.
(05 Mar 2000)
passive-aggressive personality disorder A personality disorder characterised by an indirect resistance to demands for adequate social and occupational performance; anger and opposition to authority and the expectations of others that is expressed covertly by obstructionism, procrastination, stubbornness, dawdling, forgetfulness, and intentional inefficiency.
(12 Dec 1998)
passive anaphylaxis A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations.
Synonym: antiserum anaphylaxis.
(05 Mar 2000)
passive atelectasis The pulmonary collapse that occurs due to a space-occupying intrathoracic process such as pneumothorax or hydrothorax.
(05 Mar 2000)
passive clot A clot formed in an aneurysmal sac consequent to the cessation or slowing of circulation through the aneurysm.
(05 Mar 2000)
passive congestion Congestion caused by obstruction or slowing of the venous drainage, resulting in partial stagnation of blood in the capillaries and venules.
(05 Mar 2000)
passive cutaneous anaphylaxis An evanescent cutaneous reaction occurring when antibody is injected into a local area on the skin and antigen is subsequently injected intravenously along with a dye. The dye makes the rapidly occurring capillary dilatation and increased vascular permeability readily visible by leakage into the reaction site. Pca is a sensitive reaction for detecting very small quantities of antibodies and is also a method for studying the mechanisms of immediate hypersensitivity.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • transport
    ¼ö¼ÛÇÏ´Ù
  • International Air Transport association
    ±¹Á¦ Ç×°ø¿î¼ÛÇùȸ(IATA)
  • air transport
    °øÁß¼ö¼Û;°ø¼ö
  • hypersonic transport
    ±ØÃÊÀ½¼Ó
  • hypersonic transport
    ±ØÃÊÀ½¼Ó¼ö¼Û±â
  • mass transport
    (¹ö½º,ÀüÂ÷ µîÀÇ °ø°ø ¼ö¼Û ±â°ü¿¡ ÀÇÇÑ) ´ë·® ¼ö¼Û;´ë·® ¼ö¼Û ±â°ü
  • mechanical transport
    ÀÚµ¿Â÷ ºÎ´ë
  • transport
    ¼ö¼Û(±â,¼±,±â°ü);ȲȦ;µµÃë;¿­Áß;À¯Çü¼ö )
  • transport
    ¼ö¼ÛÇÏ´Ù;µµÃë(¿­Áß)ÄÉ ÇÏ´Ù;À¯Çü¿¡ óÇÏ´Ù;Á×ÀÌ´Ù
  • transport House
    ³ëµ¿´ç º»ºÎ
  • transport ship
    ¿î¼Û¼±
  • passive
    ¼öµ¿¼ºÀÇ; ¼ø¼øÈ÷ µû¸£´Â
  • passive
    ¼öµ¿ÀÇ;¹«ÀúÇ×ÀÇ;Ȱ¹ßÇÏÁö ¸øÇÑ
  • passive belt
    ÀÚµ¿ ¾ÈÀü ¹ëÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á